Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
J Hosp Infect ; 106(3): 495-499, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32798640

ABSTRACT

A single-centre interrupted time series quasi-experimental study was undertaken to assess whether a hospital policy of selective digestive decontamination (SDD, gentamicin/amikacin with neomycin) administered to carbapenem-resistant Enterobacterales (CRE) carriers would reduce the duration of carriage and contain the spread of CRE. No significant difference in time to CRE eradication was observed between the observation (12 months, 120 patients) and intervention (12 months, 101 patients) periods. No change in the trend of new in-hospital CRE acquisitions or bacteraemia during the intervention was detected. As such, administration of SDD to CRE carriers was not effective for the eradication of carriage or controlling in-hospital CRE transmissions.


Subject(s)
Anti-Bacterial Agents/pharmacology , Carbapenems/pharmacology , Decontamination/methods , Drug Resistance, Multiple, Bacterial , Enterobacteriaceae/drug effects , Hospitals/standards , Controlled Before-After Studies , Decontamination/standards , Enterobacteriaceae Infections/prevention & control , Enterobacteriaceae Infections/transmission , Humans , Interrupted Time Series Analysis , Non-Randomized Controlled Trials as Topic , Prospective Studies
2.
J Hosp Infect ; 94(1): 54-9, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27392978

ABSTRACT

OBJECTIVES: To examine whether carbapenem-resistant Enterobacteriaceae (CRE) carriage is associated with incidence of clinical infection as a means of assessing whether the morbidity and mortality associated with these bacteria are mediated by underlying conditions or intrinsic properties of CRE. METHODS: This retrospective matched cohort study compared the incidence of invasive infections in CRE-colonized patients and matched non-carriers in the intensive care unit (ICU). The primary outcome was infection caused by CRE of the same species as the colonizing strain among CRE carriers, and infections caused by carbapenem-sensitive strains of the same organism in non-carriers. Hospital discharge and death were considered as competing events. Competing-risks hazard analysis was performed for the entire cohort and for a nested cohort matched by Acute Physiology and Chronic Health Evaluation (APACHE) II scores, stratified by matching. RESULTS: In total, 146 CRE carriers were compared with 292 non-carriers. Patients were well matched for most risk factors for Enterobacteriaceae infection, including age, renal failure, previous invasive infection, previous hospitalization, APACHE II score, length of mechanical ventilation, length of hospitalization and CRE carriage. On regression analysis, colonization with CRE was independently associated with Enterobacteriaceae infection {cause-specific hazard ratio (CSHR) 2.06 [95% confidence interval (CI) 1.03-4.09]}. On regression analysis of the APACHE-II-matched cohort (N=284), colonization with CRE remained significantly associated with Enterobacteriaceae infection [CSHR 3.32 (95% CI 1.31-8.43)]. CONCLUSIONS: Colonization with CRE was associated with at least a two-fold increased risk of infection by the colonizing strain amongst ICU patients.


Subject(s)
Anti-Bacterial Agents/pharmacology , Carbapenems/pharmacology , Carrier State/epidemiology , Critical Illness , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae/drug effects , beta-Lactam Resistance , Adolescent , Adult , Aged , Carrier State/microbiology , Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae Infections/mortality , Female , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Risk Assessment , Risk Factors , Young Adult
3.
Clin Microbiol Infect ; 20(10): O627-9, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24461043

ABSTRACT

We evaluated changes in the epidemiology of catheter-related bloodstream infections (CRBSIs) between 1996 and 2012 in a tertiary care centre in Israel. The cohort included 1754 episodes of CRBSI. The incidence of CRBSIs decreased throughout the study period, whereas 30-day mortality following bacteraemia increased. There was a linear shift toward predominance of Gram-negative bacilli throughout the study period (p for trend<0.001). In 1996, 68% (68/100) of CRBSIs were caused by Gram-positive cocci, whereas in 2012 77.8% (28/26) were caused by Gram-negative bacilli. The shift towards Gram-negative CRBSIs and the associated mortality mandates that empirical treatment for CRBSIs be directed by local epidemiology.


Subject(s)
Bacteremia/microbiology , Catheter-Related Infections/epidemiology , Gram-Negative Bacterial Infections/epidemiology , Bacteremia/epidemiology , Catheter-Related Infections/microbiology , Cross Infection/epidemiology , Cross Infection/microbiology , Gram-Negative Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/microbiology , Humans , Israel , Retrospective Studies
4.
Acta Neurochir (Wien) ; 150(7): 663-8, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18473114

ABSTRACT

Traumatic brain contusions may increase in size over time or may develop at a delay after injury. This may lead to neurological deterioration, long term morbidity or even death. Coagulation disorders after injury can contribute to progression of haemorrhage. Recombinant activated factor VII (rFVIIa) was used in 12 patients with a severe head injury who had no systemic coagulopathy but who were considered to be at risk of progression of their intracranial lesion. Twelve consecutive patients suffering from life-threatening acute head injuries from blunt (3 cases) and penetrating mechanisms were given with rFVIIa, either to prevent the expected development of brain contusion or to assist in bleeding control during surgery. In 11 patients, rFVIIa was given by the attending neurosurgeon. Two of the patients died of their severe penetrating injuries one of whom had severe vasospasm 2 days after administration of rFVIIa. The other 11 patients did not appear to suffer any treatment-related adverse effects. When the drug was given prophylactically to prevent brain resection (6 cases) or to limit the need for widening resection (5 cases), marked control was achieved in seven cases, and a lesser effect was observed in the other 4 cases. We conclude that, in a small and highly individually selected series of patients with severe head injury, the administration of rFVIIa did not lead to adverse effects. Although the majority of patients were considered to be at high risk of progression of their lesions, this occurred in only one. The early use of rFVIIa in head injured patients without systemic coagulopathy may reduce the occurrence of enlargement of contusions, the requirement of further operation, and adverse outcome. Prospective randomised controlled studies are required to investigate this.


Subject(s)
Brain Injuries/drug therapy , Drug Labeling , Factor VIIa/therapeutic use , Head Injuries, Penetrating/drug therapy , Wounds, Nonpenetrating/drug therapy , Adolescent , Adult , Blood Coagulation Disorders , Brain Injuries/surgery , Child , Child, Preschool , Disease Progression , Drug Administration Schedule , Factor VIIa/administration & dosage , Head Injuries, Penetrating/mortality , Head Injuries, Penetrating/surgery , Hemostatic Techniques , Humans , Middle Aged , Neurosurgical Procedures , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Risk Assessment , Trauma Severity Indices , Wounds, Nonpenetrating/surgery
5.
Adv Drug Deliv Rev ; 49(3): 317-23, 2001 Jul 28.
Article in English | MEDLINE | ID: mdl-11551402

ABSTRACT

Multidrug resistance (MDR) is a multifactorial process that involves elevated expression of drug transporters as well as additional biochemical changes that contribute to the drug resistant phenotype. Here we review recent results indicating the upregulation of constituents of rafts and caveolae, including glucosylceramide, cholesterol and caveolin-1, in MDR cells. Accordingly, the number of plasma membrane caveolae is greatly increased in MDR cells. The relationship between caveolin and MDR may be linked to the function of caveolin-1 in mediating cholesterol efflux, a pathway that we hypothesized to facilitate the delivery of drugs from intracellular compartments to plasma membrane resident drug transporters. An additional link seems to exist between the upregulation of GlcCer synthase and attenuation of ceramide-mediated apoptotic signaling. These adaptations may promote cell survival during chemotherapy and, hence, would be positively selected during cell exposure to cytotoxic drugs. However, the overexpression of caveolin-1, an oncosuppressive protein, may also reverse or attenuate important aspects of the phenotypic transformation of MDR cells. The molecular mechanisms by which caveolin-1 exerts its effects on cell proliferation, cell survival, and multidrug resistance remain to be fully elucidated.


Subject(s)
Caveolins/biosynthesis , Drug Resistance, Multiple/genetics , Drug Resistance, Neoplasm/genetics , Neoplasms/genetics , Up-Regulation/genetics , Animals , Caveolins/genetics , Humans , Neoplasms/metabolism
6.
Anticancer Res ; 21(2A): 1189-94, 2001.
Article in English | MEDLINE | ID: mdl-11396162

ABSTRACT

Intrinsic or acquired resistance of tumor cells to multiple cytotoxic drugs (multidrug resistance MDR) is a major cause of failure of cancer chemotherapy. MDR is often caused by elevated expression of drug transporters such as P-glycoprotein (P-gp) or multidrug resistance protein (MRP). A number of compounds, termed chemosensitizers, have little or no cytotoxic action of their own, but inhibit (P-gp) or MRP-mediated drug export and are capable of sensitizing MDR cells to the cytotoxic effects of chemotherapeutic drugs. Here we examined the ability of steroidal alkaloids of plant origin, namely the Veratrum sp. alkaloid cyclopamine and the Lycopersicon sp. alkaloid tomatidine, to act as potent and effective chemosensitizers in multidrug resistant tumor cells. Drug uptake was determined by measuring accumulation of tetramethylrosamine in multidrug resistant NCI AdrR human adenocarcinoma cells. Resistance to adriamycin and vinblastine was determined by utilizing the MTT cell survival assay. Cyclopamine and tomatidine elevate tetramethylrosamine uptake by NCI AdrR cells and sensitize the cells to the cytotoxic action of adriamycin and vinblastine. In both cases these agents are comparable in patency and efficacy to verapamil, a reversal agent commonly used in MDR research. It is concluded that steroidal alkaloids of plant origin act as inhibitors of P-gp-mediated drug transport and multidrug resistance and therefore may serve as chemosensitizers in combination chemotherapy with conventional cytotoxic drugs for treating multidrug resistant cancer.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors , Antineoplastic Agents, Phytogenic/pharmacology , Tomatine/analogs & derivatives , Tomatine/pharmacology , Veratrum Alkaloids/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Antineoplastic Agents/pharmacology , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/metabolism , Diosgenin , Doxorubicin/pharmacology , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Heterocyclic Compounds, 3-Ring/metabolism , Humans , Molecular Structure , Rhodamines , Solanaceous Alkaloids/chemistry , Solanaceous Alkaloids/metabolism , Solanaceous Alkaloids/pharmacology , Tomatine/chemistry , Tomatine/metabolism , Tumor Cells, Cultured , Veratrum Alkaloids/chemistry , Veratrum Alkaloids/metabolism , Vinblastine/pharmacology
7.
Trends Biochem Sci ; 25(11): 530-4, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11084360

ABSTRACT

Multidrug resistance (MDR) severely impairs the efficacy of cancer chemotherapy. Several protein transporters that mediate drug export have been identified, but additional adaptations appear to be necessary for full-fledged drug resistance. The cell surface density of caveolae and the expression of the caveolar coat protein caveolin are dramatically increased in MDR cancer cells. Acquisition of MDR might thus be accompanied by upregulation of caveolin-dependent cholesterol efflux pathways, raising the possibility that these same pathways are utilized for delivering drugs from intracellular compartments to the plasma membrane, where drugs can be extruded from the cells by drug efflux ATPases. The upregulation of caveolin mandates a phenotypic change of MDR cells in terms of their cholesterol homeostasis and is accompanied by loss of important features of the transformed phenotype of MDR cancer cells.


Subject(s)
Cholesterol/metabolism , Drug Resistance, Multiple/physiology , Drug Resistance, Neoplasm/physiology , B-Lymphocytes/metabolism , Caveolin 1 , Caveolins/metabolism , Cell Membrane/drug effects , Cell Membrane/metabolism , Humans
8.
Int J Cancer ; 85(6): 882-8, 2000 Mar 15.
Article in English | MEDLINE | ID: mdl-10709112

ABSTRACT

Multidrug resistance (MDR) is a major cause of failure of cancer chemotherapy and is often associated with elevated expression of drug transporters such as P-glycoprotein (P-gp) in the cancer cells. MDR is, however, accompanied by additional biochemical changes including modifications of membrane composition and properties. We have shown that MDR is associated with a massive up-regulation of caveolin expression and an elevated surface density of caveolae. We report that phospholipase D (PLD), a constituent enzyme of caveolae and detergent-insoluble glycolipid-rich membranes (DIGs), is up-regulated in human MDR cancer cells. Lysates of HT-29-MDR human colon adenocarcinoma cells, MCF-7 AdrR human breast adenocarcinoma cells and the corresponding parental drug-sensitive cells, were fractionated on discontinuous sucrose density gradients. PLD activity was found to be enriched in low density fractions that contain DIGs and caveolar membranes, and the activity in these fractions was 4- to 6-fold higher in the MDR cells compared with the parental drug- sensitive cells. Utilizing specific antibodies to PLD1 and PLD2, the distribution of PLD isoforms along the gradient was determined and the PLD localized in DIGs and caveolar membranes has been identified as PLD2. Northern blot analysis of PLD1 and PLD2 mRNA levels has indicated that PLD2 mRNA is elevated in both HT-29-MDR and MCF-7 AdrR cells. PLD1 mRNA levels were either unchanged or reduced in the MDR cells. Finally, in vivo experiments have confirmed previous results showing that activation of PLD by phorbol esters is markedly potentiated in the MDR cells. We conclude that MDR is accompanied by an increase in PLD2 activity in DIGs and caveolar membranes.


Subject(s)
Adenocarcinoma/metabolism , Breast Neoplasms/metabolism , Caveolins , Colonic Neoplasms/metabolism , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Phospholipase D/metabolism , Caveolin 1 , Gene Expression , Humans , Immunoblotting , Membrane Proteins/metabolism , Phospholipase D/genetics , Protein Isoforms , Tumor Cells, Cultured
9.
FEBS Lett ; 467(2-3): 326-32, 2000 Feb 11.
Article in English | MEDLINE | ID: mdl-10675563

ABSTRACT

Low-density detergent-insoluble membrane domains contain caveolin-1 and are enriched in a phospholipase D activity that is not PLD1. Here we show that caveolin-rich fractions, prepared from HaCaT human keratinocytes by either detergent-based or detergent-free methods, contain PLD2. Caveolar membrane PLD activity is stimulated 2-fold by low concentrations (10-30 microM) of the caveolin-1 and caveolin-2 scaffolding domain peptides, whereas it is inhibited at higher concentrations of the peptides. Immunoisolated HA-tagged PLD1 and PLD2 are not stimulated by the peptides, although both enzymes retain sensitivity to their inhibitory effect. Down-regulation of caveolin-1 expression by treatment of the cells with acetyl-leucyl-leucyl-norleucinal decreased caveolar PLD activity by 50%. Similarly, expression of an active form of the sterol regulatory element-binding protein (SREBP(1-490)) down-regulated caveolin-1 expression by 50% and decreased caveolar PLD activity by 60%. These data identify the PLD activity in caveolin-rich membranes as PLD2 and provide in vivo evidence suggesting that caveolin-1 regulates PLD2 activity.


Subject(s)
CCAAT-Enhancer-Binding Proteins , Caveolins , Cell Membrane/metabolism , Membrane Proteins/metabolism , Phospholipase D/metabolism , Transcription Factors , Caveolin 1 , Cell Extracts , Cell Line , DNA-Binding Proteins/metabolism , Detergents , Down-Regulation , Enzyme Activation , Humans , Keratinocytes/metabolism , Nuclear Proteins/metabolism , Peptides/pharmacology , Phospholipase D/antagonists & inhibitors , Sterol Regulatory Element Binding Protein 1
10.
Glycoconj J ; 17(3 -4): 253-9, 2000.
Article in English | MEDLINE | ID: mdl-11201798

ABSTRACT

The carcinogenic process involves a complex series of genetic and biochemical changes that enables transformed cells to proliferate, migrate to secondary sites and, in some cases, acquire mechanisms that make cancer cells resistant to chemotherapy. This phenomenon in its most common form is known as multidrug resistance (MDR). It is usually mediated by overexpression of P-glycoprotein (P-gp) or other plasma membrane ATPases that export cytotoxic drugs used in chemotherapy, thereby reducing their efficacy. However, additional adaptive changes are likely to be required in order to confer a full MDR phenotype. Recent studies have shown that acquisition of MDR is accompanied by upregulation of lipids and proteins that constitute lipid rafts and caveolar membranes, notably glucosylceramide and caveolin. These changes may be related to the fact that in MDR cells a significant fraction of cellular P-gp is associated with caveolin-rich membrane domains, they may be involved in drug transport and they could have an impact on drug-induced apoptosis and on the phenotypic transformation of MDR cancer cells.


Subject(s)
Caveolae/metabolism , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Membrane Lipids/metabolism , Membrane Proteins/metabolism , Animals , Caveolin 1 , Caveolins/metabolism , Cell Differentiation , Cell Transformation, Neoplastic , Humans
12.
Lipids ; 34 Suppl: S57-63, 1999.
Article in English | MEDLINE | ID: mdl-10419089

ABSTRACT

Cancer chemotherapy often fails because of the development of tumors which are resistant to most commonly used cytotoxic drugs. This phenomenon, multidrug resistance (MDR), is usually mediated by overexpression of P-glycoprotein (P-gp), an ATPase that pumps out the drugs used in chemotherapy, thereby preventing their accumulation in cancer cells and greatly reducing their cytotoxic efficacy. A large body of work indicates that MDR is associated also with marked changes in membrane lipid composition. Most notably, elevated levels of cholesterol, glycosphingolipids (e.g., glucosylceramide), and sphingomyelin have been reported. These lipids are enriched in caveolae and in membrane microdomains termed detergent-insoluble glycosphingolipid-enriched complexes (DIGs). Recently we demonstrated that in multidrug-resistant tumor cells there is a dramatic increase in the number of caveolae and in the level of caveolin-1, an essential structural constituent of caveolae. Another constituent of membrane microdomains, phospholipase D, is also elevated in MDR cells. These findings may be related to the fact that a significant fraction of cellular P-gp is associated with caveolin-rich membrane domains. The possible role of DIGs and caveolae in the acquisition and/or maintenance of the multidrug resistant phenotype is discussed.


Subject(s)
Caveolins , Cell Membrane/ultrastructure , Drug Resistance, Multiple , Neoplasms/ultrastructure , Animals , Caveolin 1 , Cell Membrane/pathology , Humans , Membrane Lipids/physiology , Membrane Proteins/genetics , Membrane Proteins/physiology , Phospholipids/physiology
13.
Biochim Biophys Acta ; 1439(2): 245-63, 1999 Jul 30.
Article in English | MEDLINE | ID: mdl-10425399

ABSTRACT

The activation of PLD is believed to play an important role in the regulation of cell function and cell fate by extracellular signal molecules. Multiple PLD activities have been characterized in mammalian cells and, more recently, several PLD genes have been cloned. Current evidence indicates that diverse PLD activities are localized in most, if not all, cellular organelles, where they are likely to subserve different functions in signal transduction, membrane vesicle trafficking and cytoskeletal dynamics.


Subject(s)
Phospholipase D/metabolism , Subcellular Fractions/enzymology , Animals , Cloning, Molecular , Detergents , GTP Phosphohydrolases/metabolism , Gene Expression Regulation, Enzymologic , Humans , Isoenzymes/analysis , Isoenzymes/metabolism , Membranes/enzymology , Phosphatidylinositol 4,5-Diphosphate/metabolism , Phospholipase D/analysis , Phospholipase D/genetics
14.
J Biol Chem ; 274(5): 2717-24, 1999 Jan 29.
Article in English | MEDLINE | ID: mdl-9915802

ABSTRACT

The activation of cellular phospholipase D (PLD) is implicated in vesicular trafficking and signal transduction. Two mammalian PLD forms, designated PLD1 and PLD2, have been cloned, but their cellular localization and function are not fully understood. Here, we report that in HaCaT human keratinocytes, as well as other cell lines, PLD activity is highly enriched in low density, Triton X-100-insoluble membrane domains that contain the caveolar marker protein caveolin-1. Similar to other PLDs, the PLD activity in these membrane domains is stimulated by phosphatidylinositol 4, 5-bisphosphate and is inhibited by neomycin. Immunoblot analysis indicated that caveolin-rich membrane domains do not contain the PLD1 isoform. Stable transfection of mouse PLD2 in Chinese hamster ovary cells greatly increased PLD activity in these domains compared with PLD activity in control Chinese hamster ovary cells transfected with vector alone. PLD activity is enriched in low density Triton-insoluble membrane domains also in U937 promonocytes, even though these cells do not express caveolin-1. In U937 cells, also, PLD1 is largely excluded from low density Triton-insoluble membrane domains. Expression of recombinant caveolin-1 in v-Src-transformed NIH-3T3 cells resulted in up-regulation of PLD activity in the caveolin-containing membrane domains. The caveolin scaffolding peptide (caveolin-182-101) modulated the caveolar PLD activity, causing stimulation at concentration of 1-10 microM and inhibition at concentrations >10 microM. We conclude that a PLD activity, which is likely to represent PLD2, is enriched in low density Triton-insoluble membrane domains. The effects of caveolin-1 expression and of the caveolin scaffolding peptide suggest that in cells that express caveolin-1, PLD may be targeted to caveolae. The possible functions of PLD in the dynamics of caveolae and related domains and in signal transduction processes are discussed.


Subject(s)
Caveolins , Membrane Proteins/biosynthesis , Phospholipase D/metabolism , 3T3 Cells , Animals , CHO Cells , Caveolin 1 , Cell Membrane/enzymology , Centrifugation, Density Gradient , Cricetinae , Detergents , Fibroblasts/enzymology , Humans , Keratinocytes/enzymology , Membrane Proteins/metabolism , Mice , Octoxynol , Peptide Fragments/metabolism , Signal Transduction , Solubility , Transfection , Tumor Cells, Cultured , U937 Cells
16.
J Biol Chem ; 273(49): 32380-3, 1998 Dec 04.
Article in English | MEDLINE | ID: mdl-9829965

ABSTRACT

Cancer chemotherapy often results in the development of multidrug resistance (MDR), which is commonly associated with overexpression of P-glycoprotein (P-gp), a plasma membrane drug efflux ATPase. It was shown recently that glycosphingolipids are elevated in MDR cells. Sphingolipids are major constituents of caveolae and of detergent-insoluble, glycosphingolipid-rich membrane domains. Here we report that multidrug-resistant HT-29 human colon adenocarcinoma cells exhibit a 12-fold overexpression of caveolin-1, a 21-kDa coat/adaptor protein of caveolae. Similar observations were made in adriamycin-resistant MCF-7 human breast adenocarcinoma cells. Caveolin-2 expression is also up-regulated in MCF-7-AdrR cells, but neither caveolin-1 nor caveolin-2 were detected in MCF-7 cells stably transfected with P-gp. The up-regulation of caveolins is associated with a 5-fold increase in the number of caveolae-like structures observed in plasma membrane profiles of HT-29-MDR cells and with the appearance of a comparable number of caveolae in MCF-7-AdrR cells. A significant fraction (approximately 40%) of cellular P-gp is localized in low density detergent-insoluble membrane fractions derived from either HT-29-MDR or MCF-7-AdrR cells. The distribution of recombinant P-gp in stably transfected MCF-7 cells was similar, even though these cells do not express caveolins and are devoid of caveolae. The possibility that caveolae contribute to the multidrug resistance and thus are co-selected with P-gp during the acquisition of this phenotype is discussed.


Subject(s)
Caveolins , Drug Resistance, Multiple/genetics , Membrane Proteins/genetics , Up-Regulation , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Caveolin 1 , Caveolin 2 , Humans , Tumor Cells, Cultured
18.
Md Med J ; 47(4): 188-90, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9709509

ABSTRACT

Group A streptococcus has emerged as a major cause of aggressive life-threatening deep-seated infections. In addition, toxic shock syndrome caused by Group A streptococcus was recognized in 1983. Group A streptococcus produces several potent exotoxins which explain the pathophysiology of these invasive infections. Other virulence factors such as M protein, which can impede phagocytosis, are associated with some Group A streptococcus. M protein and streptococcal pyrogenic exotoxins may act as super antigens. Host factors may influence the severity of infection. Blood purification techniques such as continuous renal replacement therapy and plasmapheresis can remove streptococcal exotoxins as well as inflammatory mediators. Replacement with fresh-frozen plasma corrects coagulopathy and may provide some antibody protection. Four patients with Group A streptococcus-toxic shock syndrome treated with continuous renal replacement therapy, plasmapheresis, or both showed dramatic, rapid improvement in cardiovascular dynamics and respiratory parameters. Two patients died. The mainstay of treatment for Group A streptococcus-toxic shock syndrome remains early diagnosis, aggressive surgical control of the infection, and appropriate antibiotics (i.e., penicillin and clindamycin). Flush resuscitation may rescue some patients from profound toxic shock. The mechanisms of action need to be delineated.


Subject(s)
Hemofiltration , Plasmapheresis , Resuscitation/methods , Shock, Septic/therapy , Streptococcal Infections/therapy , Streptococcus pyogenes/pathogenicity , Anti-Bacterial Agents/therapeutic use , Clindamycin/therapeutic use , Drug Therapy, Combination , Fatal Outcome , Humans , Penicillins/therapeutic use , Shock, Septic/microbiology , Streptococcal Infections/microbiology
19.
Int J Cancer ; 77(6): 928-32, 1998 Sep 11.
Article in English | MEDLINE | ID: mdl-9714066

ABSTRACT

Tamoxifen, a synthetic antiestrogen, is known for its antitumoral action in vivo; however, it is well accepted that many tamoxifen effects are elicited via estrogen receptor-independent routes. Previously, we reported that tamoxifen induces PKC translocation in fibroblasts. In the present study, we investigated the influence of tamoxifen, and several triphenylethylene derivatives, on protein kinase C (PKC) in MCF-7 human breast cancer cells. As measured by Western blot analysis, tamoxifen elicited isozyme-specific membrane association of PKC-epsilon, which was time-dependent (as early as 5 min post-treatment) and dose-dependent (5.0-20 microM). Tamoxifen did not influence translocation of alpha, beta, gamma, delta or zeta PKC isoforms. Structure-activity relationship studies demonstrated chemical requirements for PKC-epsilon translocation, with tamoxifen, 3-OH-tamoxifen and clomiphene being active. Compounds without the basic amino side chain, such as triphenylethylene, or minus a phenyl group, such as N,N-dimethyl-2-[(4-phenylmethyl)phenoxy]ethanamine, were not active. In vitro cell growth assays showed a correlation between agent-induced PKC-epsilon translocation and inhibition of cell growth. Exposure of cells to clomiphene resulted in apoptosis. Since PKC-epsilon has been associated with cell differentiation and cellular growth-related processes, the antiproliferative influence of tamoxifen on MCF-7 cells may be related to the interaction with PKC-epsilon.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Breast Neoplasms/enzymology , Protein Kinase C/drug effects , Protein Kinase C/metabolism , Tamoxifen/pharmacology , Antineoplastic Agents, Hormonal/pharmacokinetics , Blotting, Western , Breast Neoplasms/drug therapy , Dose-Response Relationship, Drug , Female , Humans , Tamoxifen/analogs & derivatives , Tamoxifen/pharmacokinetics , Tumor Cells, Cultured/enzymology
20.
Neurochem Res ; 22(4): 373-8, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9130246

ABSTRACT

The goldfish retina has been used extensively for the study of nerve regeneration. A role for phosphatidylinositol 3-kinase (PI3K) in neurite outgrowth from goldfish retinal explants has been examined by means of wortmannin (WT), a selective inhibitor of the enzyme. The presence of PI3K in retinal extracts was determined by means of immunoprecipitation as well as by an in vitro assay system for catalytic activity. The relative amount of the p85 subunit of PI3K detected by western blot in the retina following optic nerve crush was unchanged. WT inhibited goldfish brain PI3K activity at concentrations as low as 10(-9) M, approximating that reported for inhibition of mammalian PI3K's. Daily addition of 10(-8) M WT to retinal explants, activated by prior crush of the optic nerve, significantly inhibited neurite outgrowth during a 7 day in vitro culture period, while a single addition of WT to freshly explanted retina had no effect on neurite outgrowth. These results suggest that a PI3K-mediated process may be critical for nerve regrowth.


Subject(s)
Androstadienes/pharmacology , Enzyme Inhibitors/pharmacology , Goldfish , Neurites/drug effects , Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors , Retina/drug effects , Animals , Blotting, Western , Immunosorbent Techniques , Nerve Regeneration , Neurites/physiology , Optic Nerve/physiology , Phosphatidylinositol 3-Kinases , Retina/enzymology , Retina/ultrastructure , Wortmannin
SELECTION OF CITATIONS
SEARCH DETAIL
...